Genetics Institute has begun a Phase III trial of its recombinant interleukin-11 for the restoration of platelets after cancer chemotherapy. The new study follows encouraging results of a Phase II study of the treatment, in which patients who received IL-11 needed significantly fewer platelet transfusions than controls. The results of that study were presented in May. Low platelet counts can lead to increased morbidity and resource-intensive interventions, and are poorly addressed by other growth factor products, such as erythropoietin or G-CSF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze